Journal of Viral Hepatitis
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
Table of contents
- 1
-
Issue Information| 2021
- 4
-
SARS‐CoV‐2 infection in patients with a normal or abnormal liverCabibbo, Giuseppe / Rizzo, Giacomo Emanuele Maria / Stornello, Caterina et al. | 2021
- 12
-
The case for simplifying and using absolute targets for viral hepatitis elimination goalsPolaris Observatory Collaborators et al. | 2021
- 20
-
Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapyQian, Xiangjun / Liu, Shuhong / Long, Huiling et al. | 2021
- 30
-
Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistanceLiu, Yang / Chang, Silvia / Martin, Ross et al. | 2021
- 40
-
Comparison of 48‐week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta‐analysisCon, Danny / Goodwin, Thomas / Majeed, Ammar et al. | 2021
- 51
-
Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patientsLiem, Kin Seng / Wong, David K. / Fung, Scott et al. | 2021
- 61
-
Meta‐analysis: Association between hepatitis B virus preS mutation and hepatocellular carcinoma riskWungu, Citrawati Dyah Kencono / Ariyanto, Fis Citra / Prabowo, Gwenny Ichsan et al. | 2021
- 72
-
Impact of a nurse‐led enhanced monitoring, management and contact tracing intervention for chronic hepatitis B in England, 2015‐2017Beebeejaun, Kazim / Amin‐Chowdhury, Zahin / Letley, Louise et al. | 2021
- 80
-
Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive studyWu, Jian / Yu, Jiong / Shi, Xiaowei et al. | 2021
- 89
-
Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapyRodríguez‐Tajes, Sergio / Miralpeix, Anna / Costa, Josep et al. | 2021
- 95
-
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovirChang, Jin Won / Lee, Jae Seung / Lee, Hye Won et al. | 2021
- 105
-
The effect of universal infant vaccination on the prevalence of hepatitis B immunity in adult solid organ transplant candidatesKoc, Özgür M. / Kuypers, Dirk / Dupont, Lieven J et al. | 2021
- 112
-
Improved quality of life following direct‐acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub‐Saharan Africa (the SHARED study)Van Nuil, Jennifer Ilo / Umutesi, Grace / Shumbusho, Fabienne et al. | 2021
- 121
-
Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or ‘re‐diagnose’ infections is effective in AustraliaPrince, David Stephen / Pipicella, Joseph Louis / Fraser, Melissa et al. | 2021
- 129
-
Real‐world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in JapanMizokami, Masashi / Liu, Lauren J. / Fujiyama, Naoto et al. | 2021
- 142
-
Reduced work absenteeism in patients with hepatitis C treated with second‐generation direct‐acting antiviralsLindgren, Peter / Löfvendahl, Sofia / Brådvik, Gunnar et al. | 2021
- 147
-
Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus‐co‐infected patients in MyanmarMin Thaung, Yin / Chasela, Charles S. / Chew, Kara W. et al. | 2021
- 159
-
Persistent augmentation of central arterial stiffness following viral clearance by direct‐acting antivirals in chronic hepatitis CChen, Ju‐Yi / Cheng, Pin‐Nan / Chiu, Yen‐Cheng et al. | 2021
- 168
-
Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infectionJohnson, Philip J. / Berhane, Sarah / Walker, Alex J. et al. | 2021
- 177
-
Effect of baseline resistance‐associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta‐analysisZhang, Yonggui / Jiang, Xuefeng / Zhao, Yuyang et al. | 2021
- 186
-
Characterization of hepatitis E virus natural infection in farmed rabbitsLi, Shuangshuang / Li, Manyu / He, Qiyu et al. | 2021
- 196
-
Hepatitis E virus genome detection in commercial pork livers and pork meat products in GermanyPallerla, Srinivas Reddy / Schembecker, Sonja / Meyer, Christian G. et al. | 2021
- 205
-
Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up studyBeudeker, Boris J. B. / Groothuismink, Zwier M. A. / de Man, Robert A. et al. | 2021
- 209
-
Telemedicine HCV treatment in department of corrections results in high SVR in era of direct‐acting antiviralsSyed, Taseen A. / Cherian, Reena / Lewis, Shawn et al. | 2021
- 213
-
Hepatitis delta virus propagation enabled by hepatitis C virus—Scientifically intriguing, but is it relevant to clinical practice?Pflüger, Lisa Sophie / Schulze zur Wiesch, Julian / Polywka, Susanne et al. | 2021
- 217
-
In support of community‐based hepatitis C treatment with triage of people at risk of cirrhosis to specialist careWade, Amanda J. / Doyle, Joseph S. / Draper, Bridget et al. | 2021
- 219
-
Authors’ reply to letter: In support of community‐based hepatitis C treatment with triage of people at risk of cirrhosis to specialist carePhillips, Clare / O’Sullivan, Margaret / Schulkind, Jasmine et al. | 2021
- 221
-
Rely to: ‘Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues’Tao, Ya‐Chao / Chen, En‐Qiang et al. | 2021